{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:27:52Z","timestamp":1793647672396,"version":"4.5.1"},"reference-count":41,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.2967\/jnumed.123.266524","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T18:00:32Z","timestamp":1710439232000},"page":"580-585","source":"Crossref","is-referenced-by-count":15,"title":["Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer"],"prefix":"10.2967","volume":"65","author":[{"given":"Kyeara N.","family":"Mack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary V.","family":"Samuels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas M.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara D.","family":"Viray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Mandleywala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory L.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Hollingsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"2024061312401054000_65.4.580.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21456"},{"key":"2024061312401054000_65.4.580.2","unstructured":"Special section: ovarian cancer. In: Cancer Facts & Figures: 2018. American Cancer Society; 2018:28\u201343."},{"key":"2024061312401054000_65.4.580.3","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.3802\/jgo.2018.29.e32","article-title":"Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism","volume":"29","author":"Li","year":"2018","journal-title":"J Gynecol Oncol."},{"key":"2024061312401054000_65.4.580.4","doi-asserted-by":"publisher","DOI":"10.2217\/17520363.1.4.513"},{"key":"2024061312401054000_65.4.580.5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1406619111"},{"key":"2024061312401054000_65.4.580.6","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182473292"},{"key":"2024061312401054000_65.4.580.7","first-page":"14","article-title":"Serum sialyl Tn antigen as a prognostic marker in patients with epithelial ovarian cancer","volume":"44","author":"Kobayashi","year":"1992","journal-title":"Nippon Sanka Fujinka Gakkai Zasshi."},{"key":"2024061312401054000_65.4.580.8","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.7b00325"},{"key":"2024061312401054000_65.4.580.9","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.ymthe.2020.12.029","article-title":"Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer","volume":"29","author":"Thomas","year":"2021","journal-title":"Mol Ther."},{"key":"2024061312401054000_65.4.580.10","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/1078-0432.CCR-21-1798","article-title":"ImmunoPET of ovarian and pancreatic cancer with AR9.6, a novel MUC16-targeted therapeutic antibody","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin Cancer Res."},{"key":"2024061312401054000_65.4.580.11","doi-asserted-by":"publisher","DOI":"10.1007\/s13139-014-0315-z"},{"key":"2024061312401054000_65.4.580.12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0936-6555(05)80168-2","article-title":"OC125 immunoscintigraphy in ovarian carcinoma: a comparison with alternative methods of assessment","volume":"2","author":"Maughan","year":"1990","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"2024061312401054000_65.4.580.13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0028-2243(90)90035-Y","article-title":"Comparative study of RIS with the 131I-OC 125 F(ab\u2032)2 Mab and CT scan prior to second look operation for ovarian cancer","volume":"37","author":"Papazefkos","year":"1990","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"key":"2024061312401054000_65.4.580.14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF00842786","article-title":"A prospective evaluation of OC125 and magnetic resonance imaging in patients with ovarian carcinoma","volume":"16","author":"Perkins","year":"1990","journal-title":"Eur J Nucl Med."},{"key":"2024061312401054000_65.4.580.15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/BF00253598","article-title":"Radioimmunoscintigraphy of ovarian cancer with 131-iodine labeled OC-125 antibody fragments","volume":"15","author":"Barzen","year":"1989","journal-title":"Eur J Nucl Med."},{"key":"2024061312401054000_65.4.580.16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/oxfordjournals.annonc.a058488","article-title":"Usefulness of imaging ovarian cancer recurrence with In-111-labeled monoclonal antibody (OC 125) specific for CA 125 antigen. The INSERM Research Network (Nantes, Rennes, Reims, Vuillejuif, Saclay","volume":"4","author":"Peltier","year":"1993","journal-title":"Ann Oncol."},{"key":"2024061312401054000_65.4.580.17","first-page":"1033","article-title":"Evaluation of the diagnostic usefulness of CA125 immunoscintigraphy for ovarian carcinoma follow-up after treatment: contribution of this technique in Grenoble University Medical Center","volume":"84","author":"Vuillez","year":"1997","journal-title":"Bull Cancer."},{"key":"2024061312401054000_65.4.580.18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0090-8258(89)90169-8","article-title":"Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer","volume":"34","author":"Finkler","year":"1989","journal-title":"Gynecol Oncol."},{"key":"2024061312401054000_65.4.580.19","first-page":"3249s","article-title":"A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma","volume":"5","author":"Mah\u00e9","year":"1999","journal-title":"Clin Cancer Res."},{"key":"2024061312401054000_65.4.580.20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0090-8258(90)90049-Q","article-title":"Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125","volume":"38","author":"Muto","year":"1990","journal-title":"Gynecol Oncol."},{"key":"2024061312401054000_65.4.580.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2009.05.007"},{"key":"2024061312401054000_65.4.580.22","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2010.13"},{"key":"2024061312401054000_65.4.580.23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nucmedbio.2019.04.005","article-title":"A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals","volume":"71","author":"Sharma","year":"2019","journal-title":"Nucl Med Biol."},{"key":"2024061312401054000_65.4.580.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-9140(02)00457-5"},{"key":"2024061312401054000_65.4.580.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.056036"},{"key":"2024061312401054000_65.4.580.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.229013"},{"key":"2024061312401054000_65.4.580.27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.anucene.2014.08.023","article-title":"Overview of particle and heavy ion transport code system PHITS","volume":"82","author":"Sato","year":"2015","journal-title":"Ann Nucl Energy."},{"key":"2024061312401054000_65.4.580.28","first-page":"473","article-title":"MIRDCalc V 1.0: a community spreadsheet tool for organ-level radiopharmaceutical absorbed dose calculations [abstract]","volume":"59","author":"Kesner","year":"2018","journal-title":"J Nucl Med."},{"key":"2024061312401054000_65.4.580.29","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3925"},{"key":"2024061312401054000_65.4.580.30","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"2024061312401054000_65.4.580.31","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat Rev Clin Oncol."},{"key":"2024061312401054000_65.4.580.32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.nucmedbio.2020.04.006","article-title":"Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation","volume":"86-87","author":"Nemieboka","year":"2020","journal-title":"Nucl Med Biol."},{"key":"2024061312401054000_65.4.580.33","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-014-0060-4"},{"key":"2024061312401054000_65.4.580.34","doi-asserted-by":"publisher","DOI":"10.1097\/00006231-199709000-00013"},{"key":"2024061312401054000_65.4.580.35","first-page":"115","article-title":"The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99mTc labelled monoclonal antibodies in cancer patients","volume":"1","author":"McQuarrie","year":"1998","journal-title":"J Pharm Pharm Sci."},{"key":"2024061312401054000_65.4.580.36","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/ijc.2910500616","article-title":"The mechanism of hepatic uptake of a radiolabelled monoclonal antibody","volume":"50","author":"Boyle","year":"1992","journal-title":"Int J Cancer."},{"key":"2024061312401054000_65.4.580.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2012.07.002"},{"key":"2024061312401054000_65.4.580.38","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1021\/acs.molpharmaceut.6b01130","article-title":"Preloading with unlabeled CA19.9 targeted human monoclonal antibody leads to improved PET imaging with 89Zr-5B1","volume":"14","author":"Houghton","year":"2017","journal-title":"Mol Pharm."},{"key":"2024061312401054000_65.4.580.39","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.2967\/jnumed.120.256776","article-title":"Exploiting the MUC5AC antigen for noninvasive identification of pancreatic cancer","volume":"62","author":"Henry","year":"2021","journal-title":"J Nucl Med."},{"key":"2024061312401054000_65.4.580.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3667"},{"key":"2024061312401054000_65.4.580.41","doi-asserted-by":"publisher","DOI":"10.2217\/imt.10.114"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.266524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T19:45:17Z","timestamp":1718307917000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.266524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,14]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,1]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.2967\/jnumed.123.266524"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.266524","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,14]]}}}